ME03090B - Pirazolamidni spoj i njegova upotreba u medicini - Google Patents

Pirazolamidni spoj i njegova upotreba u medicini

Info

Publication number
ME03090B
ME03090B MEP-2018-110A MEP2018110A ME03090B ME 03090 B ME03090 B ME 03090B ME P2018110 A MEP2018110 A ME P2018110A ME 03090 B ME03090 B ME 03090B
Authority
ME
Montenegro
Prior art keywords
pirazolamide
medicine
compound
pirazolamide compound
Prior art date
Application number
MEP-2018-110A
Other languages
German (de)
English (en)
French (fr)
Inventor
Takahisa Motomura
Gakujun Shomi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51536938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03090(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of ME03090B publication Critical patent/ME03090B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78Benzoic acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MEP-2018-110A 2013-03-15 2018-03-14 Pirazolamidni spoj i njegova upotreba u medicini ME03090B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361791164P 2013-03-15 2013-03-15
JP2013053195 2013-03-15
JP2013127318 2013-06-18
EP14763385.3A EP2975028B1 (en) 2013-03-15 2014-03-14 Pyrazole-amide compound and medicinal uses therefor
PCT/JP2014/056825 WO2014142290A1 (ja) 2013-03-15 2014-03-14 ピラゾール-アミド化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
ME03090B true ME03090B (me) 2019-01-20

Family

ID=51536938

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2018-110A ME03090B (me) 2013-03-15 2018-03-14 Pirazolamidni spoj i njegova upotreba u medicini

Country Status (31)

Country Link
US (4) US9040717B2 (me)
EP (3) EP3805205A1 (me)
JP (6) JP6208603B2 (me)
KR (1) KR102226096B1 (me)
CN (1) CN105051015B (me)
AU (1) AU2014230569B2 (me)
BR (1) BR112015022077A2 (me)
CA (1) CA2904985C (me)
CL (1) CL2015002608A1 (me)
CY (1) CY1120173T1 (me)
DK (1) DK2975028T3 (me)
ES (1) ES2663789T3 (me)
HR (1) HRP20180635T1 (me)
HU (1) HUE036672T2 (me)
IL (1) IL241355B (me)
LT (1) LT2975028T (me)
ME (1) ME03090B (me)
MX (1) MX373716B (me)
MY (1) MY182884A (me)
NO (1) NO2975028T3 (me)
PE (1) PE20151595A1 (me)
PH (1) PH12015501993A1 (me)
PL (1) PL2975028T3 (me)
PT (1) PT2975028T (me)
RS (1) RS57188B1 (me)
RU (1) RU2664532C2 (me)
SG (1) SG11201507327TA (me)
SI (1) SI2975028T1 (me)
SM (1) SMT201800196T1 (me)
TW (1) TWI633885B (me)
WO (1) WO2014142290A1 (me)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
WO2014142290A1 (ja) * 2013-03-15 2014-09-18 日本たばこ産業株式会社 ピラゾール-アミド化合物およびその医薬用途
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN114716377A (zh) * 2016-07-29 2022-07-08 日本烟草产业株式会社 吡唑-酰胺化合物的制造方法
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MX2020008126A (es) * 2018-02-01 2020-09-18 Japan Tobacco Inc Compuesto de amida heterociclica nitrogenada y su uso para fines medicos.
CN112638377A (zh) * 2018-09-11 2021-04-09 日本烟草产业株式会社 含有吡唑酰胺化合物的慢性肾脏病的治疗或预防剂
CN113490492B (zh) 2019-03-04 2024-09-27 日本烟草产业株式会社 吡唑酰胺化合物的非晶质固体分散体
MX2022010950A (es) * 2020-03-04 2022-10-07 Japan Tobacco Inc Compuesto triciclico fusionado y uso farmaceutico del mismo.
CN117897382A (zh) * 2021-09-01 2024-04-16 日本烟草产业株式会社 含氮三环化合物及其药物用途
KR102769218B1 (ko) * 2022-09-28 2025-02-24 주식회사 제이디바이오사이언스 신규한 플루오렌 유도체 및 이의 용도
WO2025079741A1 (ko) * 2023-10-10 2025-04-17 경북대학교 산학협력단 항노화용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827285B1 (fr) * 2001-07-10 2003-12-05 Rhodia Chimie Sa Reactif et procede pour la perfluoroalcoylation
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
TW200418825A (en) 2002-12-16 2004-10-01 Hoffmann La Roche Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
CA2843439A1 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
AU2005214249A1 (en) 2004-02-20 2005-09-01 Astellas Pharma Inc. Fluorene derivative
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
RU2007147844A (ru) * 2005-05-23 2009-06-27 Джапан Тобакко Инк. (Jp) Пиразольное соединение и содержащее его терапевтическое средство для лечения сахарного диабета
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
FR2936173B1 (fr) * 2008-09-22 2012-09-21 Snecma Procede pour la fabrication d'une piece en titane avec forgeage initial dans le domaine beta
AR074797A1 (es) 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
BRPI1013937A2 (pt) 2009-04-22 2016-08-09 Astellas Pharma Inc compostos de ácido carboxílico
TW201506015A (zh) * 2013-03-15 2015-02-16 Japan Tobacco Inc 茀化合物的水合物以及其結晶
WO2014142290A1 (ja) * 2013-03-15 2014-09-18 日本たばこ産業株式会社 ピラゾール-アミド化合物およびその医薬用途
JP2015028009A (ja) 2013-07-01 2015-02-12 日本たばこ産業株式会社 ピラゾール−アルコール化合物およびその医薬用途
WO2015002118A1 (ja) 2013-07-01 2015-01-08 日本たばこ産業株式会社 フルオレン-アミド化合物およびその医薬用途

Also Published As

Publication number Publication date
IL241355B (en) 2019-03-31
RS57188B1 (sr) 2018-07-31
PH12015501993B1 (en) 2016-01-11
MX373716B (es) 2020-05-08
IL241355A0 (en) 2015-11-30
CA2904985C (en) 2021-07-20
US9040717B2 (en) 2015-05-26
PH12015501993A1 (en) 2016-01-11
KR102226096B1 (ko) 2021-03-09
BR112015022077A2 (pt) 2017-07-18
CA2904985A1 (en) 2014-09-18
AU2014230569B2 (en) 2017-11-23
AU2014230569A1 (en) 2015-10-08
KR20150131221A (ko) 2015-11-24
JP6208603B2 (ja) 2017-10-04
SI2975028T1 (en) 2018-07-31
JP2022000453A (ja) 2022-01-04
ES2663789T3 (es) 2018-04-17
EP3805205A1 (en) 2021-04-14
JP2019194197A (ja) 2019-11-07
SMT201800196T1 (it) 2018-05-02
US20140296315A1 (en) 2014-10-02
RU2664532C2 (ru) 2018-08-20
TW201501711A (zh) 2015-01-16
SG11201507327TA (en) 2015-10-29
HRP20180635T1 (hr) 2018-06-01
LT2975028T (lt) 2018-04-10
US20180256547A1 (en) 2018-09-13
WO2014142290A1 (ja) 2014-09-18
US20160074364A1 (en) 2016-03-17
EP3348545A1 (en) 2018-07-18
CN105051015B (zh) 2018-09-25
JP2018021061A (ja) 2018-02-08
PL2975028T3 (pl) 2018-10-31
CL2015002608A1 (es) 2016-03-04
JP2015024984A (ja) 2015-02-05
PT2975028T (pt) 2018-03-29
PE20151595A1 (es) 2015-11-24
RU2015144182A3 (me) 2018-03-06
HUE036672T2 (hu) 2018-07-30
CY1120173T1 (el) 2018-12-12
JP2018188449A (ja) 2018-11-29
RU2015144182A (ru) 2017-04-24
EP2975028A1 (en) 2016-01-20
MY182884A (en) 2021-02-05
JP2020189855A (ja) 2020-11-26
EP2975028B1 (en) 2018-02-21
TWI633885B (zh) 2018-09-01
EP2975028A4 (en) 2016-08-17
US20200163937A1 (en) 2020-05-28
HK1215808A1 (en) 2016-09-15
MX2015012743A (es) 2016-02-19
CN105051015A (zh) 2015-11-11
DK2975028T3 (en) 2018-03-12
NO2975028T3 (me) 2018-07-21

Similar Documents

Publication Publication Date Title
FIC20260008I1 (fi) tsuranoloni ja sen farmaseuttisesti hyväksyttävät suolat
FIC20260001I1 (fi) Oletsarseeni ja sen farmaseuttisesti hyväksyttävät suolat
ME03090B (me) Pirazolamidni spoj i njegova upotreba u medicini
NO2021012I1 (no) avapritinib and pharmaceutically acceptable salts thereof
HUE037275T2 (hu) Gyógyszer-kombináció
EP2953116A4 (en) Display apparatus and device
DK3020408T3 (da) Traditionel kinesisk medicinsammensætning og fremstilling og anvendelse heraf
BR302013005965S1 (pt) Configuração aplicada em otomana
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
PT3064491T (pt) Derivado de sulfonamida e sua utilização medicinal
BR112016004943A2 (pt) aparelho médico e uso
DK3590499T3 (da) Inhalerbare lægemidler
IL244751A0 (en) Cyclic thianouracil-carboxamides and their use
EP3041028A4 (en) LAMINATE AND APPLICATION THEREOF
BR302013005862S1 (pt) Configuração aplicada em coador
FI20135799L (fi) Kaivon yhteydessä käytettävä turvalaite
BR302014001901S1 (pt) Configuração aplicada em organizador
FR3007291B1 (fr) Composition cicatrisante et utlisation
BR112015024661A2 (pt) silo e silo elevado
PL2769662T3 (pl) Zmywarka do naczyń i sposób obsługi zmywarki do naczyń
DK2972363T3 (da) Immunpotenserende nanobærerlægemiddel
HRP20181735T1 (hr) Liposom za topikalnu primjenu i njegova uporaba
DE112014002244A5 (de) Infusionslösung
FR3013565B1 (fr) Bagage a peson